Maplight Therapeutics, INC Form 4 insider transactions

Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc., sold 12,248 shares of common stock on October 15, 2026 for $7.84 per share.

Jonathan Gillis, CAO and Interim CFO of MapLight Therapeutics, Inc., sold 10,167 shares of common stock on October 15, 2026 for $8.08 per share.

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., sold 11,513 shares of common stock on October 15, 2026 for $8.08 per share.

Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., sold 9,020 shares of common stock on October 15, 2026 for $8.08 per share.

Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, Inc., sold 15,355 shares of common stock on October 15, 2026 for $8.08 per share.

Christopher A. Kroeger, Chief Executive Officer and a Director of MapLight Therapeutics, Inc., sold 73,691 shares of common stock on October 15, 2026 for $8.08 per share.

Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., sold 16,509 shares of common stock on September 16, 2026 for $11.67 per share.

Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

Jonathan Gillis, CAO and Interim CFO of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

Christopher A. Kroeger, Chief Executive Officer and a Director of MapLight Therapeutics, Inc., reported multiple transactions in common stock on August 17, 2026.

Catalyst4, Inc. reported changes in beneficial ownership of MapLight Therapeutics, Inc. common stock on August 14, 2026.

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., sold 22,082 shares of common stock on August 3, 2026 for $12.54 per share.

Catalyst4, Inc. reported changes in beneficial ownership of MapLight Therapeutics, Inc. common stock on July 28, 2026.

Troy Cox, a Director of MapLight Therapeutics, Inc., purchased 15,620 shares of common stock on July 28, 2026 for $9.52 per share.

Jonathan Gillis, CAO and Interim CFO of MapLight Therapeutics, Inc., sold 36,979 shares of common stock on July 15, 2026.

Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc., sold 36,284 shares of common stock on July 15, 2026.

Christopher A. Kroeger, Chief Executive Officer and a Director of MapLight Therapeutics, Inc., sold 147,639 shares of common stock on July 15, 2026.

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., sold 18,267 shares of common stock on July 15, 2026.

Kristopher Hanson, General Counsel of MapLight Therapeutics, Inc., sold 16,508 shares of common stock on July 15, 2026.

Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, Inc., sold 47,158 shares of common stock on July 15, 2026.

Troy Cox, a director at MapLight Therapeutics, Inc., was granted restricted stock units and stock options on June 23, 2026, as part of the company's non-employee director compensation policy.

Martin Babler, a Director at MapLight Therapeutics, Inc., was granted restricted stock units and stock options on June 23, 2026.

Timothy John Garnett, a Director at MapLight Therapeutics, Inc., reported the acquisition of 3,932 restricted stock units and the grant of a stock option for 14,902 shares.

Nanna Liebach, a Director at MapLight Therapeutics, Inc., was granted restricted stock units and a stock option on June 23, 2026, as part of the company's non-employee director compensation policy.

George Pavlov, a Director at MapLight Therapeutics, Inc., acquired restricted stock units and a stock option, signaling continued commitment and potential future equity gains.

Maria C. Walker, a Director at MapLight Therapeutics, Inc., acquired restricted stock units and stock options on June 23, 2026, as part of the company's non-employee director compensation policy.

CEO Christopher Kroeger sold 118,235 shares of MapLight Therapeutics under a pre-arranged Rule 10b5-1 trading plan.